健康产业创新服务平台
资讯
业务发展与探索
数字化与科技创新
先锋科研
政策动态
研报专区
找我合作
sci天天读
γδ T细胞的肿瘤免疫治疗
SCI20 October 2024Cancer immunotherapy by γδ T cells(Science; IF:44.7)
Oct. 20, 2024
分子成像支持多特异性癌症抗体的开发
SCI19 October 2024Molecular imaging supports the development...
Oct. 19, 2024
纳武利尤单抗免疫治疗期间新抗原免疫原性格局和肿瘤生态系统的演变
SCI18 October 2024Neoantigen immunogenicity landscapes and e...
Oct. 18, 2024
定义癌前病变:癌症界面临的巨大挑战
SCI17 October 2024Defining precancer: a grand challenge for the cancer community
Oct. 17, 2024
临床验证游离细胞DNA片段组检测增强肺癌早期发现
SCI16 October 2024Clinical Validation of a Cell-Free DNA Fra...
Oct. 16, 2024
联合 KRAS 抑制和免疫治疗在本地 PDAC 模型中产生持久的完全反应
SCI15 October 2024Combined KRAS inhibition and immune therap...
Oct. 15, 2024
ctDNA 分层策略在晚期非小细胞肺癌化疗联合 PD-1抑制剂治疗中的应用
SCI14 October 2024Circulating tumor DNA-based stratification...
Oct. 14, 2024
转铁蛋白受体靶向嵌合体用于膜蛋白降解
SCI13 October 2024Transferrin receptor targeting chimeras fo...
Oct. 13, 2024
代谢紊乱相关癌症中的巨噬细胞和T细胞
SCI12 October 2024Macrophages and T cells in metabolic disor...
Oct. 12, 2024
KRAS-突变非小细胞肺癌对活性RAS抑制的反应和耐受机制
SCI11 October 2024Mechanisms of Response and Tolerance to Ac...
Oct. 11, 2024
乳腺癌数据统计2024
SCI10 October 2024Breast cancer statistics 2024(CA Cancer J Clin. IF:503.1)
Oct. 10, 2024
PD-1 表达的表观遗传调节可改善耗竭的 T 细胞功能和病毒控制
SCI9 October 2024Epigenetic tuning of PD-1 expression improv...
Oct. 9, 2024
胸部计算机断层扫描检测到的肺结节的数据驱动风险分层和精确管理
SCI8 October 2024Data-driven risk stratification and precisi...
Oct. 8, 2024
CAF诱导的物理限制控制实体瘤中T细胞的状态和定位
SCI7 October 2024CAF-induced physical constraints controllin...
Oct. 7, 2024
单细胞染色质可及性揭示了原发性人类癌症的恶性调控程序
SCI6 October 2024Single-cell chromatin accessibility reveals...
Oct. 6, 2024
造血系统衰老通过促进IL-1⍺驱动的紧急骨髓生成来促进癌症
SCI5 October 2024Hematopoietic aging promotes cancer by fuel...
Oct. 5, 2024
体内树突状细胞重编程用于癌症免疫治疗
SCI4 October 2024In vivo dendritic cell reprogramming for cancer immunotherapy
Oct. 4, 2024
癌症诊断和预后预测的病理学基础模型
SCI3 October 2024A pathology foundation model for cancer dia...
Oct. 3, 2024
Datopotamab Deruxtecan vs Docetaxel用于既往治疗的晚期或转移性NSCLC
SCI2 October 2024Datopotamab Deruxtecan Versus Docetaxel for...
Oct. 2, 2024
在不可切除的III期ALK阳性NSCLC化疗后,联合ALK酪氨酸激酶抑制剂对比Durvalumab或观察
国庆节快乐SCI1 October 2024Consolidation ALK Tyrosine Kinase Inhi...
Oct. 1, 2024
previous
Page 1
next